The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | N | Nervous system | |
2 | N02 | Analgesics | |
3 | N02A | Opioids | |
4 | N02AJ | Opioids in combination with non-opioid analgesics |
Code | Title | |
---|---|---|
N02AJ01 | ||
N02AJ02 | ||
N02AJ03 | ||
N02AJ06 | ||
N02AJ07 | ||
N02AJ08 | ||
N02AJ09 | ||
N02AJ13 | ||
N02AJ14 | Tramadol and dexketoprofen | |
N02AJ15 | ||
N02AJ16 | ||
N02AJ17 | ||
N02AJ18 | ||
N02AJ19 | ||
N02AJ22 | ||
N02AJ23 |
Active Ingredient | Description | |
---|---|---|
Codeine and Ibuprofen |
Ibuprofen is an NSAID which acts peripherally, inhibiting prostaglandin synthesis and the action of chemical mediators of pain. In humans, ibuprofen reduces inflammatory pain, swellings and fever. Codeine is a centrally acting weak analgesic. Codeine exerts its effect through μ opioid receptors, although codeine has low affinity for these receptors, and its analgesic effect is due to its conversion to morphine. The combination of a well tolerated peripheral analgesic with a centrally acting analgesic provides optimum pain relief with a lower potential for producing side effects. |
|
Codeine and Paracetamol |
The combination of paracetamol with codeine is a well-tolerated and effective analgesic. It consists of complementary active substances with different properties, but with common indication, the relief of pain. A special feature of the combination of paracetamol and codeine is the rapid onset of action after 10-20 minutes and the duration of action for 4-6 hours. |
|
Dihydrocodeine and Paracetamol |
The combination of dihydrocodeine and paracetamol is used to treat aches and pains, including headaches, migraines, muscle and joint pain, period pain and toothache. |
|
Oxycodone and Paracetamol |
Oxycodone and paracetamol combination is used to relieve moderate to severe pain. Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions. |
|
Tramadol and Dexketoprofen |
Tramadol hydrochloride is a centrally acting synthetic opioid analgesic. It is a non-selective, partial agonist of μ-, δ- and κ-opioid receptors with a higher affinity for μ-receptors. Tramadol has an antitussive action. In contrast to morphine, analgesic doses of tramadol over a wide range have no respiratory depressant effect. Dexketoprofen is an analgesic, anti-inflammatory and antipyretic drug, which belongs to the non-steroidal anti-inflammatory group of drugs. The mechanism of action of non-steroidal antiinflammatory drugs is related to the reduction of prostaglandin synthesis by the inhibition of cyclooxygenase pathway. |
|
Tramadol and Paracetamol |
Tramadol is an opioid analgesic that acts on the central nervous system. Tramadol is a pure non selective agonists of the µ, δ, and κ opioid receptors with a higher affinity for the µ receptors. Tramadol has an antitussive effect. The precise mechanism of the analgesic properties of paracetamol is unknown and may involve central and peripheral effects. Tramadol/paracetamol is positioned as a step II analgesic in the WHO pain ladder and should be utilised accordingly by the physician. |
Title | Information Source | Document Type | |
---|---|---|---|
CETVIO Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
CO-TIPOL Hard capsule | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
CO-TIPOL Suppository | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
CODANOL Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
COGESIC Tablet | Marketing Authorisation Holder | MPI, Generic | |
EMCOZIN Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
KAPAKE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
LENIZAK Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
MEDOTRAMOL Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
MYBULEN Capsule | Health Products Regulatory Authority (ZA) | MPI, Generic | |
PAINAMOL PLUS Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
PARCOTEN Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
PROLATE Oral solution | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
SKUDEXA Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TRAMACET Film coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ULTRACET Coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |